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Uterine transplantation has been proposed as a possible solution to absolute uterine factor infertility untreatable by any other
option. Since the ﬁrst human attempt in 2000, various teams have tried to clarify which immunosuppressant would be most
suitable for protecting the allogeneic uterine graft while posing a minimal risk to the fetus. Cyclosporine A (CsA) is an
immunosuppressant widely used by transplant recipients. It is currently being tested as a potential immunosuppressant to be used
during UTn. Its eﬀect on the mother and fetus and its inﬂuence upon the graft during pregnancy have been of major concern. We
review the role of CsA in UTn and its eﬀect on pregnant transplant recipients and their oﬀspring.
1.Background
Uterine transplantation (UTn) has been proposed as a
possible solution to absolute uterine factor infertility (AUFI)
untreatable by any other option [1]. The inability to expe-
rience a pregnancy, give birth, and bring up a child because
of infertility issues may be one of the most traumatic and
devastating situations to aﬀect a woman or couple, with
the capacity to have a severely detrimental eﬀect on the
quality of life of both parties [2–4]. The term “infertile” is
an all-encompassing term and includes women with AUFI.
Causes which render women “unconditionally infertile” are
either congenital, namely, M¨ ullerian duct anomalies, or
acquired causes (such as leiomyomata, radiation damage,
intrauterine adhesions, or premenopausal hysterectomy for
obstetric bleeding or cervical/endometrial cancer).
Tremendous advances have been made during the last
decades in the ﬁelds of transplantation and reproductive
medicine, in particular, the ﬁrst reports of successful trans-
plantation of a solid organ, the kidney [5, 6], and live birth
after IVF [7]. Transplantation surgery today includes types
of organ/tissue transplantation that will enhance the quality-
of-life as exempliﬁed by transplantation of the hand [8], the
abdominal wall [9], the larynx [10], and the face [11], with
the aim to add UTn to the list.
UTn was ﬁrst performed in a human in 2000 on a 26-
year-old female who had previously lost her uterus as a
result of postpartum haemorrhage. The event granted much
needed impetus for research into UTn, which since then has
been a slow, methodical process within an animal setting
involving multiple institutions and disciplines over several
continents. Research has focused on several important areas,
mainly surgical, immunological, and reproductive aspects.
The second UTn attempt in a human model is anticipated
in the not-too-distant future.
A major obstacle to UTn remains immunological rejec-
tion of the transplanted graft. The process of rejection
in allogeneic UTn was ﬁrst described by two studies in
1969 [12, 13], the decade in which UTn research was
ﬁrst published. At that time, UTn commonly involved en
bloc autotransplantation of a combination of the diﬀerent
reproductive organs: uterus, fallopian tubes, and ovaries.
Since then, assisted reproductive technologies such as in
vitro fertilization (IVF) have addressed many of the causes2 Journal of Transplantation
of infertility. However, for women who suﬀer from AUFI,
surrogacy, adoption, or lifetime infertility remains the only
option. The hope is that, with continued advances in
transplantation surgery and control of tissue rejection, UTn
can bring an end to AUFI by allowing a select group of
women to become mothers [14].
2. TransplantSurgery
The treatment of choice for certain end-stage organ diseases,
such as kidney and liver failure, is organ transplantation.
Since 1956 and Joseph Murray’s ﬁrst successful solid-organ
transplant, involving the transfer of a kidney between geneti-
cally identical twins, this ﬁeld has progressed rapidly because
of considerable improvements in two vital areas: surgical
methodology and immunology. With respect to the latter,
it is important to recognise that without full understanding
of the risks posed by the rejection process and subsequent
development of immunosuppressants, transplantation as
we understand it today would not be possible. It would
certainly involve a smaller group of possible donors (only
syngeneic),resultinginagreatlyreducednumberofpotential
beneﬁciaries.
Research of graft rejection between two allogeneically
diﬀerent individuals resulted in the development of immu-
nosuppressive agents in the 1960s. 5-mercaptopurine/azathi-
oprine, in combination with corticosteroids, was the ﬁrst
to be marketed for use. Next came the discovery of the
calcineurin inhibitor cyclosporine A (CsA) in the late 1970s
[15]. These drugs, especially CsA, represented at the time a
widely sought panacea and caused a rapid advancement in
clinical organ transplantation.
The risks posed by immunosuppressants are well known,
and the potential teratogenicity of certain agents still poses
a considerable threat. At the time of the ﬁrst healthy birth
to a transplant recipient in 1958 [16], pregnancy was not
recommended by both transplant surgeons and obstetricians
[17]. However, approximately 14,000 births (more since this
result was ﬁrst published in 2002) among transplant women
have been reported worldwide [18], resulting in a change
of opinion, whereby restored fertility is now a recognized
desirable outcome following transplantation [19, 20].
3. Immunosuppression in General
Sir Peter Brian Medawar ﬁrst introduced the idea of im-
munosuppressants as possible agents that could be used
to prevent and treat allograft rejection. Currently short-
term eﬀects have been very positive but chronic rejection
is still a major issue and long-term use has its drawbacks.
These are mainly related to nonspeciﬁc suppression of
the host immune system, which may cause any of the
following: bacterial and viral infections, nephrotoxicity and
neurotoxicity with chronic renal failure, newly diagnosed
diabetes mellitus, hyperlipidaemia, leucopoenia, and even
cancer [15, 21].
Deciding on the type, dose, and monitoring of immuno-
suppressants prescribed is best made within a multidis-
ciplinary team setting including an obstetrician, so as to
maximize the eﬃcacy and minimize potential toxicity [19].
As immunosuppressants can cross the human placental
barrier and enter the fetal circulation, possibly aﬀecting the
immune system of the fetus, obstetric input is paramount
[22]. Which immunosuppressant is administered depends
very much on the age and comorbidities of the patient,
type of transplanted organ, length of time that the patient
is expected to live postoperatively, and the transplant centre.
Drug combinations and immunosuppressant protocols vary
considerably between centres.
Medications used to suppress immunologic activity are
chosen based on the stage of the transplant process. In
the induction phase, intravenous immunoglobulin is usually
combined with a cornerstone immunosuppressant such as
a cytokine modulator (CsA), purine-related analogue (aza-
thioprine), and a purine synthesis inhibitor (mycophenolate
mofetil). CsA or tacrolimus are then usually continued as
“maintenancetherapy,”incombinationwithglucocorticoids,
mycophenolate mofetil/sodium, or azathioprine. In addi-
tion, alkylating agents (cyclophosphamide and chlorambu-
cil) and biologic response modiﬁers (TNF antagonists) can
be used [15, 24].
The ﬁrst record of the use of immunosuppressants in
pregnancy was in 1967 by Board et al. This team used aza-
thioprine and prednisolone to prevent allogeneic rejection in
a kidney recipient [25]. The risk that immunosuppressants
pose to both the mother and fetus, with respect to potential
birth defects, needs to be fully investigated and understood.
This is especially important as the number of female
transplant recipients of child-bearing age is increasing.
Furthermore, problems related to thalidomide exposure in
the 1960s clearly portray the devastating consequences of
the release of unknown drug into the general population
[26]. Table 1 summarises the risk categories of commonly
used immunosuppressants, including CsA. The level of risk
is dependent on whether an animal or human is receiving
the immunosuppressant as well as the dose and route of
administration of the immunosuppressant. Fetal risk ranges
from severe abnormalities related to structural development
that are diagnosable either at any stage of pregnancy or
only in the third trimester, to those that are only subtle and
apparent after delivery [27].
4. Cyclosporine
CsA is a cyclic nonribosomal decapeptide derived from the
fungus, Tolypocladium inﬂatum, ﬁrst isolated in Norway in
1969. It was ﬁrst used to successfully prevent kidney [28]
and liver transplant rejection [29], with oﬃcial approval for
CsA use arriving in 1983. Apart from transplant medicine,
CsA is also used in a number of autoimmune diseases:
dermatological-psoriasis; severe atopic dermatitis; pyoderma
gangrenosum; rheumatologic-rheumatoid arthritis and gas-
trointestinal such as ulcerative colitis and Crohn’s disease.
The main role of CsA is to interfere with signaling
pathways important for the clonal expansion of immuno-
competent lymphocytes. It does this by forming complexes
through binding to an intracellular cytosolic protein calledJournal of Transplantation 3
Table 1: Immunosuppressant risk categories according to US Food and Drug Administration [18].
Category Drug Animal/human studies
A Paracetamol No risk in human studies
B Corticosteroids (Prednisolone) No risk in animal studies or Risk in animal studies but that risk not
demonstrated in human studies
Tacrolimus (Prograft)
C Rapamycin Fetal risk demonstrated in animal studies but no adequate and well-controlled
studies in humans. Drugs can be used if potential beneﬁts outweigh risks
Cyclosporine A (Neoral,
Sandimmune, Gengraf)
D
Mycophenolate Mofetil
(CellCept, Myfortic) Fetal risk demonstrated in human studies. In exceptional circumstances, drugs
can be used if potential beneﬁts outweigh risks
Azathioprine (Imuran)
Table 2: Eﬀect of CsA on leucocytes [23].
Cell type Eﬀect
Bl y m p h o c y t e
(i) ↓ cytokine production by T cells leading to inhibition of proliferation
(ii) B-cell activation leading to induction of apoptosis
(iii) Ligation of immunoglobulin leading to inhibition of proliferation
Tl y m p h o c y t e s
(i) ↓ in IL-2/3/4, GM-CSF, TNF-α expression
(ii) ↓ levels of IL-2 resulting in ↓ production of T cells
(iii) ↓ level of Ca2+-dependent exocytosis of granule-associated esterases
Granulocyte (i) ↓ level of Ca2+-dependent exocytosis of granule-associated esterases
cyclophilin. The CsA-cyclophilin complex inhibits the phos-
phatase activity of a calcium-activated enzyme called cal-
cineurin. Calcineurin is responsible for transmitting signals
from the T-cell receptor to the nucleus. It is activated
following the rise of intracellular Ca2+ levels in response to
T-cell receptor binding. Calcineurin then dephosphorylates
the transcription factor NF-AT (nuclear factor of activated
T cells) in the cytoplasm, allowing for its migration to
the nucleus which leads to the induction of transcription
of genes coding for IL-2, CD40 ligand, and Fas ligand
[30]. Therefore, by inhibiting the function of calcineurin,
the CsA-cyclophilin complex manages to block clonal T-
cell proliferation in response to the host immune system
recognizing a speciﬁc antigen as being foreign. This results
in reduced function of eﬀector T cells [30]. CsA also acts on
other immunopotent cells and has a large variety of other
immunological eﬀects (Table 2)[ 23].
5. Use of Cyclosporine in
UterineTransplantation
5.1. Human Attempt. Research into UTn restarted before
its afore-mentioned milestone in 2000, that is, the ﬁrst
human attempt. This attempt may have been premature,
with little characterization or understanding of the rejection
response prior to the operation. CsA was administered 6
hours prior to surgery and postoperatively (4mg/kg/body
weight divided into two doses to assure a serum trough
level of 200ng) along with azathioprine, prednisolone and a
boost by antithymocyte globulin. CD+4/CD+8 ratio in blood
and Doppler of uterine blood ﬂow were the only techniques
employed to monitor possible rejection patterns. The ﬁrst
rejection episode occurred on the ninth postoperative day
and the patient was treated by increasing the oral doses
of CsA and azathioprine and administering an intravenous
dose of prednisolone. The rejection resolved after 2 days but
only after antithymocytic globulin was given. On the 99th
day, following symptoms suggestive of uterine infarction, a
hysterectomy was performed. Histopathologic examination
conﬁrmed thrombosis of uterine vessels, and, interestingly,
therewasnosignsofrejectionwithapparentviabilityofboth
tubes [31].
5.2. Animal Models. To date, CsA has not been used as
an immunosuppressant in the few cases where the primary
objective was to bring about pregnancy following UTn. 4
cases involved a syngeneic model which removed the need
for an immunosuppressant [32–35]. In October of the last
year, an allogeneic uterine transplant reported resorbed
pregnancies in 4 out of 5 pregnant rats, with only tacrolimus
used as an immunosuppressant [36].
However, CsA has been tried as an immunosuppressant
in UTn studies where achieving pregnancy was not the
primary objective. Described below are all studies where CsA
was administered as an immunosuppressant in UTn. Its ﬁrst
recorded use was in 1986 when Conﬁno et al. described
unilateral nonvascular UTn in 18 rabbit models. Out of
those, 6 were allogeneic transplants with administration of
CsA. Three rabbits developed pelvic abscesses while in three4 Journal of Transplantation
other rabbits both the endometrial and myometrial layers
survived for four weeks [37]. Br¨ annstr¨ om group went on
to describe the acute rejection response in a mouse model,
with signs of rejection from day 2 to day 5, represented
by increased density of CD3+ T cells in the myometrium
and endometrium, and full rejection with massive necrosis
and ﬁbrosis by day 28 [38]. Having demonstrated that
predominately neutrophils, macrophages, and CD+4/CD+8
T cells were responsible for acute rejection [39], CsA was
ﬁrst tried as a potential immunosuppressant in a mouse
UTn model. 5 mice acted as control (no CsA given) and 5
received either 10 or 20mg/kg/day of CsA. As expected the
extent of necrosis demonstrated on histology was decreased
in the CsA mice. Apoptosis and inﬂammation were less
prominent in grafts taken from the recipient mice that
had received a higher CsA dose. Therefore, the authors
concluded that administration of CsA can evidently delay
the progress of rejection of grafted uteri. However rather
surprisingly, T-cell inﬁltration was not suppressed with the
CD8+countsigniﬁcantlyhigherinthetwoallogeneicgroups
receiving CsA compared with the control group [40]. This
outcome may be explained by CsA inhibition of activation-
induced cell death (AICD) of cytotoxic T cells by major
histocompatibility complex-peptide complexes [40, 41].
CsAhasalsobeentriedinalarge-animalmodel.Asingle-
agent CsA was eﬀective for maintaining a uterus transplant
in several nonhuman primate models. Clinical signs, serum
analysis, and ultrasound examination of the uterus and
vascular ﬂow through the anastomosis were all used to
monitor rejection and graft viability. In the ﬁrst, the target
CsA trough was 150ng/mL, with a similar dose response
to other solid organ transplants (5mg/kg/day; dose mean:
15.5ng/mL; 8mg/kg/day mean: 191.8 ± 59.3ng/mL). This
proved enough to prevent acute rejection in the immediate
posttransplant period. However, during the second postop-
erativemonth,thefollowingsymptomswerereported:recip-
ient weight loss and pelvic oedema. An apparent rejection
episode was managed with additional immunosuppressants,
high-dose steroids, and tacrolimus. No further rejection
episodes occurred after that [1, 42]. The second model also
revealed satisfactory results with CsA use. It was the only
immunosuppressantadministeredwithlevelsmonitoredand
adjusted appropriately. On examination of the uterus a year
after UTn, minimal signs of rejection were revealed with
intact anastomosis [1, 43].
CsA and tacrolimus were administered to the same sheep
model with successful results [44]. Initially, tacrolimus was
given for 12 days intravenously, followed by CsA only orally.
The uterus and ovary were harvested en bloc, ﬂushed ex vivo,
and transplanted in an orthotopic position by vascular anas-
tomosis,eitherbetweenindividuals(allotransplantation,n =
9) or back to the same animal (autotransplantation, n =
7). Immunosuppression after allotransplantation consisted
of administration of intravenous CsA (2–5mg/kg) or oral
tacrolimus(0.3–0.5mg/kg)for3weeks,andtheanimalswere
then examined and euthanized. Autotransplanted ewes were
evaluated at 7 weeks and then introduced to a ram (n = 5)
for assessment of transplant function. In allotransplanted
animals the ovary and uterus showed normal appearance in
33% (2 of 6) of CsA-treated and 66% (2 of 3) of tacrolimus-
treated ewes at 3 weeks after transfusion. Histology analysis
of these conﬁrmed normal appearance. Analysis of uteri that
diverged from normal gross appearance showed diﬀerent
degrees of inﬂammation, inﬁltration of leukocytes and
necrosis. In the autotransplanted group, two animals were
sacriﬁced7weeksaftertransplantationshowingnormaluteri
and ovaries. Vaginal examination and analysis of serum
progesteroneconﬁrmedsatisfactoryhealingintheremaining
5 animals before a ram was introduced. Four ewes mated
and three conceived, bearing one twin and two singleton
pregnancies with normal foeti at termination on day 90
(n = 1) and day 140 (n = 2) of pregnancy. In conclusion,
a model for UTn has been developed in the ewe with results
indicating that immunosuppression by tacrolimus, rather
than cyclosporine, is to be preferred in this model [44].
Furthermore, Avison et al. used CsA in a swine model.
Ten transplants were performed, with 5 animals alive and
healthy at the end of followup (0.5–12 months). Immuno-
suppression given was as follows: 10–20mg/day of methyl-
prednisolone for a month and oral CsA (10mg/kg/day) as
maintenance. Rejection episodes during the 2nd and 3rd
months after transplantation were treated successfully with
increased doses of oral CsA [45].
The above ﬁndings suggest that CsA administered at
higher doses or used in combination with another type of
immunosuppressant, as is the case in other organ transplants
(kidney,liver,andheart),wouldbeanidealwayofpreventing
UTn rejection. The eﬀects of immunosuppressants on the
maternal immune system have been well documented, and,
therefore, viral serology for cytomegalovirus as well as
microbiological cultures of vaginal smears repeated monthly
may be helpful. Levels of CsA and other immunosuppressive
drugs in the blood should be monitored, thus permitting
adjustmentsofdrugdoserelativetograftfunctionandphysi-
ological changes of pregnancy.
Importantly, the risks to mother and fetus will be not
diﬀerent from those faced by renal, hepatic, or cardiac
transplant patients undergoing pregnancy. All UTn patients
should be managed within a multidisciplinary team setting,
including a transplant immunologist. The care pathway
would be very similar to any pregnant patient with a
transplanted organ [46]. Visual inspection of the trans-
planted cervix would of course likely provide clinical clues
of the graft’s condition. In order to create a controlled
environment during the labour process, a Caesarean section
will be advisable. Removal of the transplanted uterus can be
performed at the time of the Caesarean.
6. Cyclosporineand Pregnancy
For CsA to become the immunosuppressant of choice in
UTn, its role in pregnancy and, therefore, its eﬀect on both
mother and fetus would have to be better understood. We
describe below the diﬀerent ways in which CsA can impact
during the course of a pregnancy.
6.1. Correct Dosing-Graft Acceptance versus Toxicity. The
aim of organ transplantation is to cure or at least reverseJournal of Transplantation 5
end-stage organ failure. Severe forms of both kidney and
liver disease are associated with infertility. A signiﬁcant
proportion of all kidney and liver end-organ (thought to
be higher than 50%) damage suﬀerers experience menstrual
cycle-associated pathology, ranging from amenorrhoea to
dysmenorrhoeaandirregularcycles[47].Ithasbeendemon-
strated that following successful solid organ transplantation,
as the graft begins to slowly function, normal endocrine
and fertility function returns to the patient, allowing her to
attemptpregnancy[47,48].Bothrenalandlivertransplanted
women report a restoration of their ovarian and menstrual
function within an average of six to ten months follow-
ing transplantation [49–51]. The hypothalamo-pituitary-
ovarian axis in a transplant patient is thought to be function-
ing as normally as it would in a nontransplant female, with
serum gonadotrophin and prolactin levels very similar in the
two groups [49]. Higher levels of oestradiol are reported in
renal graft patients in comparison to nontransplant women
[52]. Therefore, restoration of fertility is often used as a
variable to assess the function of the transplanted graft, with
the two outcomes tending to mirror each other [47, 53].
Data on pregnancy outcomes of transplant patients is
derived from voluntary registries, case reports, and retro-
spective centre studies. Davison and Baylis have summarised
the outcomes of 2040 live births among female solid organ
transplant recipients recorded in three major registries
(the European Dialysis and Transplantation Association
Registry, the UK Transplant Pregnancy Registry, and the
National Transplantation Pregnancy Registry (NTPR) in the
USA) [18]. Overall conclusions, particularly when analysing
the NTPR data, indicate a higher incidence of maternal
hypertension and preeclampsia in transplanted patients,
with the number varying with the organ transplanted
[54]. NTPR has reported hypertension rates of 47–73% in
pregnant kidney-transplant recipients, a much higher rate
than those demonstrated in pregnant women who have
received liver, heart, or lung transplants. CsA is known to
induce hypertension, and its more frequent use in kidney
transplantation may explain such a high percentage [18].
Data derived from Radomski et al. [55] and Armenti et al.
[56–58] revealed a hypertension incidence increase from
52% to 56–63% when nonemulsiﬁed CsA was administered
and 68–73% when emulsiﬁed CsA (Neoral) was used. A
similar picture is found with preeclampsia whose incidence
varies from 25 to 45% with CsA use [55–58], with a third
of all pregnant women receiving kidney or pancreas-kidney
transplants reporting this diagnosis and only 25% of liver,
heart, or lung recipients [18, 46, 52, 59].
The accuracy with which preeclampsia is diagnosed is
open to debate. The two main markers of preeclampsia,
hypertension and proteinuria, are found in many transplant
patients (especially kidney) prior to pregnancy [17]. Fur-
thermore, CsA increases uric acid levels, a blood marker
for diagnosing preeclampsia, and therefore causes it to be
less reliable [18, 60]. Both hypertension and preeclampsia
must be either prevented or if already present controlled
adequately. Indirectly, they lead to premature membrane
rupture and subsequent preterm delivery and low birth
weight [56, 57, 60]. This may explain why up to half of
all pregnancies in transplant recipients, especially with renal
grafts, end in preterm delivery [18, 46, 61, 62].
Administering the appropriate dose of CsA remains a
challenge. A dose must be “low enough” not to bring about
any toxicity within the mother or the neonate but at the
same time “high enough” so as not to result in organ reje-
ction. With respect to CsA, there may be no perfect dose but
a “trial and error” approach which accepts the considerable
variation in circulating drug levels associated with the
increase in a pregnant woman’s extracellular volume and
altered pharmacokinetics [63]. Thomas et al. assessed the
eﬀects of pregnancy on CsA levels in six renal allograft
patients and found that, after adjusting for dose, ﬁve of the
six patients had declines in CsA level during pregnancy [63].
Frustratingly, there is very limited evidence, especially when
searching for case-control studies of immunosuppressive
levels in pregnant transplant women, to determine whether a
drop in the blood concentration of an immunosuppressant
below the prepregnancy level invariably leads to rejection
[18]. Donaldson et al. presented a case of a pregnancy after
bilateral lung transplantation. CsA levels dropped during
the pregnancy which was complicated by acute and chronic
allograft rejection, resulting in irreversible loss of lung
function [64]. Furthermore, according to NTPR outcomes,
pregnantkidney-transplantrecipientswhotookhigherdoses
of CsA before and during pregnancy maintained normal
graft function in comparison to those patients who had
smaller doses [18, 65].
Long-term data following long-term CsA use with
regards to allograft loss, maternal survival after pregnancy
(due to an increased risk of viral diseases and neoplasm
secondary to immunosuppressants [66]), and oﬀspring out-
comes of transplant recipients is rather limited. Long-term
outcomes focusing on physical and mental development of
oﬀspring and immunological and oncological pathologies
later in life are necessary [46]. The comparison of pregnancy
outcomes in a single group of women before and after
transplantation can be of use. Currently, only one study by
K¨ all´ en et al. has carried out such work. It concluded that
despite an initial increased risk for preeclampsia, growth
restriction, preterm birth, and the risk of miscarriage, the
odds of these 4 outcomes were all statistically similar before
and after transplantation [67]. In fact, smoking and mother’s
comorbidity were the single most important determinants of
fetal and neonatal well-being.
6.2. CsA and Toxicity during Pregnancy. The use of CsA
throughoutpregnancyexposesthefetustopotentialfetotoxic
andteratogenicagents.CsA,likeotherimmunosuppressants,
is required during the entire gestational period, with mainte-
nance of appropriate CsA dose. It must not be reduced with-
out reason or even worse, believing that natural nonspeciﬁc
maternal immunosuppression can prevent allogeneic graft
rejection. Any random reduction in CsA dosing may lead to
rejection of transplanted organs, with two maternal deaths
reported as due to discontinuation of immunosuppressive
medications during pregnancy [68]. What makes this issue
particularly challenging is the fact that such eﬀects, if any, of
CsA on the neonate with regards to phenotype and growth6 Journal of Transplantation
may be diﬃcult to determine and may not be obvious at
birth. In addition, underling maternal comorbidity, together
with coexisting use of other types of immunosuppression
and/or general medication, may act as a confounding factor
and can therefore confuse the issue of whether it is the actual
immunosuppressant responsible for the maternal or fetal
eﬀects [18].
CsA-related toxicity is a result of two important charac-
teristics. First, the molecular targets of calcineurin inhibitors
such as CsA are found in other cells types, which means that
CsA may act on other tissues [23]. This explains why CsA
is particularly toxic to both maternal and fetal renal tissue
[69].IntrauterineCsAexposureateachstageofdevelopment
can induce permanent nephron and hepatic damage in the
oﬀspring. Fein et al. injected 30mg/kg body weight of CsA
into pregnant mice on days 6–8 or 10–12 of gestation.
This dose did not raise the maternal mortality rate but
histological examination revealed pathological alterations in
the maternal thymus, liver, kidney, and spleen. Interestingly,
most changes had disappeared by 1 week following the
last injection. With respect to pregnancy, CsA reduced the
number of viable embryos and increased the number of
embryos resorbed. Organogenesis was not aﬀected by the
drug but CsA had an apparent embryotoxic eﬀect [70].
Two studies by Tendron-Franzin et al. evaluated the
impact of CsA on embryonic renal development in a rabbit
model [71, 72]. Initially, twenty-one pregnant rabbits were
injected with 10mg/kg body weight of CsA for 5 days,
either from days 14–18 or days 20–24 of gestation. The
latter group demonstrated a reduced number of living
pups, which were also growth-retarded. The former group
exhibited normal fetal growth, and blood concentrations
of CsA matched human data. Examinations of kidneys at
birth suggested nephron mass and number reduction by 25
and 33% in both groups. Despite compensatory adaptation
of the existing nephrons, renal function could face chronic
problems because of the presence of segmental glomerular
sclerosis [71]. The second study was also conducted in a
rabbit model to assess the long-term systemic and renal
eﬀects of a CsA-induced (10mg/kg body weight injected)
nephron reduction. CsA intrauterine exposure led to (a)
permanent nephron deﬁcit, (b) glomerular, tubular and
intrarenal haemodynamic dysfunction, (c) enlarged kid-
neys with numerous tubular and glomerular lesions, and
(d) an endothelin-dependent systemic hypertension that
worsened with age. This resulted in systemic hypertension
and progressive chronic renal insuﬃciency in adulthood,
suggesting that infants who are born to mothers treated with
CsA during pregnancy must have long-term surveillance of
kidney function in the form of blood tests and imaging [72].
For comparative purposes, we should emphasise that the
dosages of CsA given in the animal models are applicable
to those used in humans. CsA dosage depends on whether
the drug is used at the induction stage or maintenance stage
as well as on the institution and country. In the UK, adult
dosage for induction therapy varies from 10 to 20mg/kg.
In humans, the story is rather diﬀerent with no similar
eﬀects identiﬁed [73, 74]. Shaheen et al. [75]a n dG i u -
dice et al. [76] investigated renal function with the latter
using inulin clearance, para-aminohippuric acid clearance,
microalbuminuria, and electrolyte reabsorption rate in the
oﬀspring of transplant patients from birth to the age of
seven. They concluded that, in children born to transplanted
womentakingCsA,renalfunctiondevelopsnormallydespite
prolonged exposure in utero.
CsAcancrosstheplacentaandthusenterfetalcirculation
[77], easily detected in the placenta, amniotic ﬂuid as well as
fetal tissues [78]. The level of CsA in fetal blood tends to be
half the CsA level in the mother [75, 79] but even this level is
enough to pose signiﬁcant immunosuppression to the fetus
[77]. Higher levels in the placenta and umbilical cord than in
maternal blood have been recorded [18, 77, 79]. According
to the Food and Drug Administration (FDA), CsA belongs to
the Category C designation which indicates that human risk
cannot be ruled out because studies in humans are lacking
andstudiesinanimalsareeitherpositiveforriskorlackingall
together. Until now, no consistent congenital malformations
in the oﬀspring of rodents exposed to CsA during pregnancy
have been noted; however, a small number of reports have
recorded:cataracts,growthdelay,andfetotoxiceﬀectsathigh
doses [69, 80, 81].
There have been isolated reports of birth defects in
humans but because of such small numbers and inconsistent
patterns of defects it is diﬃcult to conclude whether the
incidence is secondary to CsA exposure or another factor
[82]. The prevalence of major structural malformations in
pregnantwomenwithoutgenetichistoryordiseaseisaround
3p e r c e n t[ 17] which was approximately the same as the
ﬁgure reported by NTPR (4-5 percent) [58]. A meta-analysis
of15studiesbyBaretal.concludedthatCsAdoesnotappear
to be a major human teratogen but may be associated with
increased rates of prematurity [83].
6.3. Cyclosporine and Fetal Immune Proﬁle. The primary
target of CsA in transplant recipients is the host immune
system. As discussed above, apart from downgrading the
maternal immune system, CsA manages to also enter fetal
circulation during pregnancy. One would assume that this
would result in CsA interrupting normal fetal T-cell devel-
opment. However, only a limited number of studies have
included the fetal and neonatal immune system as an end-
point [18]. They suggest that immunosuppressants can have
ap r o f o u n de ﬀect on the development of an immune system.
Heeg et al. exposed pregnant mice to a calcineurin inhibitor
(CsA and tacrolimus) and, by doing so, brought about
dysfunctional T-cell reactivity and prevented the generation
of single positive mature T cells in newborn mice. Drugs
were administered during the ﬁnal third of the gestational
periodwhichisanimportanttimeforimmunedevelopment.
Also noticeable was the formation of hypoplastic peripheral
lymphatic organs [84, 85]. Another similar study involving
a rat model showed a series of immune perturbations
including a decreaseddelayedtype hypersensitivity response,
splenic B cell number, and functional impairment during
postnatal maturation [86].
Immunologic studies conducted in human neonates
have so far been inconclusive. Some have reported normalJournal of Transplantation 7
immunologic function in infants exposed to immunosup-
pressants in utero [87, 88]. Another study of continuous
exposure of CsA in utero in six infants born to female kidney
transplant recipients demonstrated a seemingly impaired T-,
B-, and NK-cell development and/or maturation (reduction
in numbers and expression of CD25 and HLA-DR on T
cells and CD5 on B cells), with most eﬀects still apparent at
one year [89]. Takhaashi et al. investigated the lymphocyte
subpopulations in cord blood of six newborn infants born to
mothers following renal transplantation. All were receiving
CsA, as well as azathioprine and methylprednisolone. The
number of B cells and the percentage of B cell in total
mononuclear cells were signiﬁcantly lower in these infants
at one and three months of age, with no signiﬁcant
decrease between numbers of CD2+, CD4+, or CD8+ cells.
This may suggest that the B-cell line is more sensitive to
immunosuppressants in utero than the T-cell line [90].
AnotherthreatposedbyCsAandimmunosuppressionof
the fetal immune system in general is a risk of autoimmune
disease in the oﬀspring of transplant recipients [88, 91].
In a particular study, CsA was administered to pregnant
mice to study the eﬀects of passively transferred CsA on
the developing immune system which clearly altered the
developing immune system. Embryos were partially depleted
of CD4+ CD8− cells and 11 of 50 oﬀspring born to
CsA-treated mothers developed signiﬁcant levels of IgG
autoantibodiestogastricantigens.Twoanimalsdevelopedan
extensive mononuclear cell inﬁltrate in the gastric mucosa
resembling autoimmune gastritis [92]. However, in the
MotheriskPrograminCanada,theincidenceofautoimmune
diseases in the oﬀspring of mothers with kidney transplants
included one child with insulin-dependent diabetes mellitus
and two children with asthma. These rates mimic the
expected rates of the two disorders among the general
population [93]. More studies are required for deﬁnitive
conclusions.
6.4. Cyclosporine and Fetal Reproductive Proﬁle. Part of the
decision making process as to which immunosuppressant
should be used depends on the eﬀect of that immuno-
suppressant on pregnancy speciﬁc hormones. Groth et al.
published the ﬁrst study assessing reproductive health in
animals exposed to immunosuppressive drugs (CsA) in
utero. They also investigated the eﬀect of CsA on pregnancy
and fetal development [94]. Their results demonstrated that
direct maternal and in utero exposure to high doses of CsA
reduced implantation rates, fetal survival, and adolescent
growth but did not aﬀect oﬀspring fertility. This correlation
was dose dependent, with higher doses exhibiting a more
pronounced negative eﬀect. The reduced implantation rates
havebeenreportedinprevioussimilarexperimentsinvolving
murine models [69, 70]. In a particular study by Mason et
al., female Lewis rats were given 10–25mg/kg/day of CsA
from the time of mating to 20 days after coitus. Higher CsA
doses caused a powerful fetotoxic eﬀect, resulting in a high
incidence of fetal mortality or miscarriage, suggesting that
CsAcanaﬀecttheendometriumordeciduainanegativeway
[81]. In fact there is evidence which reveals a possible link
between CsA and suboptimal ovarian function, as a result of
hindrance to sex steroid secretion at the time of ovulation
[95, 96]. This in turn leads to issues with conception which
tends to occur at the time of ovulation. The endometrial
layer depends on the sex steroids for its maintenance, and, if
their secretion is impaired, the lining is also dysfunctional.
As a result conception is impaired, an eﬀect even more
pronounced as a result of the role CsA plays in both T-cell
and NK-cell activation [97].
Finally, it is worth noting that the eﬀect of CsA upon
the fetus continues after delivery if the mother breastfeeds.
Data regarding breast feeding by mothers taking immuno-
suppressive medication is still relatively sparse. According
to The American Academy of Paediatrics, steroids such as
prednisoloneposenorisk,whereasbreastfeedingbymothers
taking CsA is actively discouraged. No recommendations
regarding azathioprine or tacrolimus exist in the literature
[98]. Measuring CsA levels in breast milk is currently not
a recognised tool as levels vary greatly between diﬀerent
transplant recipients, from undetectable to equal to those
in the maternal serum. Flechner et al. reported a term
pregnancy in a CsA and prednisone-treated female cadaveric
renal allograft recipient. A male child, small for gestational
age at 2370g, was born at 38 weeks of gestation with neither
congenital anomalies nor nephrotoxicity or hepatotoxicity.
CsA determined by a radioimmunoassay was present in the
fetal circulation during gestation and maternal breast milk at
similar concentrations to those in the mother. Interestingly,
fetal serum at birth displayed 25% suppression of a third-
party mixed lymphocyte culture compared with control
incubations, adding to the body of evidence which advises
against the breastfeeding of children by CSA-treated mothers
[77]. Whether exposure to CsA through breast milk poses
a big enough risk to outweigh the beneﬁts of breast feeding
remains an unknown topic.
7. Conclusion
In UTn, maintaining a healthy pregnancy is the most impor-
tant marker of graft function. Monitoring of the patient and
the fetus should be managed by a multidisciplinary team,
including a transplant surgeon, high-risk obstetrician, and
neonatologist [99]. The pregnant transplant recipient must
consult frequently and well in advance of the labour process,
with the neonatologist and the paediatrician so that both the
patient and team are prepared for any untoward outcomes.
CsA serum levels should be monitored closely with attention
paid to graft function including visual inspection of the
cervix.
CsA is a widely used immunosuppressant by transplant
recipients, required to maintain adequate graft and maternal
survival. Its eﬀect on the fetus and the variation of its
inﬂuence upon the graft during pregnancy has been of
major concern. Continuing advances and modiﬁcations
in CsA therapy, coupled with an increasing number of
successful pregnancy outcomes after all types of solid organ
transplantation, have resulted in a greater conﬁdence in CsA
useduring pregnancy.Whenusedincombinationwithother
immunosuppressants, CsA has demonstrated a more potent8 Journal of Transplantation
protective inﬂuence on the transplanted graft, with minimal
side eﬀects and a negligible teratogenic eﬀect.
Finally, it is worth highlighting that despite the theoret-
ical risks of CsA and other types of immunosuppressants to
mother and fetus, successful pregnancies are now considered
the norm in transplant recipients. Importantly, successful
pregnancy is deﬁned as one without evidence of malforma-
tions in the newborn, as well as worsening of graft function
(because of gestational factors or prepregnancy morbidity)
in comparison to the prepregnancy graft state.
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